• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高 AMH 水平的 IVF 结局:多囊卵巢综合征与非多囊卵巢综合征的重点比较。

IVF outcome with a high level of AMH: a focus on PCOS versus non-PCOS.

机构信息

Division of Reproductive Immunoendocrinology, Department of Obstetrics & Gynecology, Faculty of Medicine, University of Indonesia-Cipto Mangunkusumo National Hospital, Jl. Pangeran Diponegoro No.71, Kenari, Kec. Senen, Kota Jakarta Pusat, Daerah Khusus Ibukota Jakarta, 10430, Indonesia.

Department of Obstetrics and Gynecology, Faculty of Medicine, University of Indonesia-Cipto Mangunkusumo National Hospital, Jl. Pangeran Diponegoro No.71, Kenari, Kec. Senen, Kota Jakarta Pusat, Daerah Khusus Ibukota Jakarta, 10430, Indonesia.

出版信息

BMC Womens Health. 2022 May 14;22(1):172. doi: 10.1186/s12905-022-01756-4.

DOI:10.1186/s12905-022-01756-4
PMID:35568864
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9107208/
Abstract

BACKGROUND

The purpose of this research was to investigate whether high AMH levels in PCOS patients resulted in different IVF outcomes compared to those in non-PCOS patients.

METHODS

A retrospective cohort study was conducted involving 238 women undergoing IVF who had AMH levels > 4 ng/ml. Participants were divided into two groups: PCOS and non-PCOS.

RESULTS

The median AMH level was significantly higher in the PCOS group (7.59 ± 4.61 ng/ml vs. 5.91 ± 2.22 ng/ml, p < 0.001). The PCOS group required less gonadotropin but yielded more oocytes after stimulation. Significantly more participants from the PCOS group (41.5% [n = 39]) developed a hyperresponse to ovarian stimulation compared to the non-PCOS group (26.4% [n = 38]) (OR = 1.978, 95% CI 1.138-3.488; p = 0.015).

CONCLUSION

There were significant differences in terms of total doses of gonadotropin and the number of oocytes retrieved in the PCOS and non-PCOS groups. Women with PCOS and high AMH levels have a higher risk of hyperresponse after ovarian stimulation than women without PCOS.

摘要

背景

本研究旨在探讨多囊卵巢综合征(PCOS)患者的 AMH 水平是否高于非 PCOS 患者,进而对体外受精(IVF)结局产生影响。

方法

采用回顾性队列研究,纳入 238 例行 IVF 且 AMH 水平>4ng/ml 的患者。根据是否患有 PCOS 将患者分为 PCOS 组和非 PCOS 组。

结果

PCOS 组的 AMH 水平中位数显著高于非 PCOS 组(7.59±4.61ng/ml 比 5.91±2.22ng/ml,p<0.001)。与非 PCOS 组相比,PCOS 组需要更少的促性腺激素,但刺激后产生的卵母细胞更多。与非 PCOS 组(26.4%[n=38])相比,PCOS 组(41.5%[n=39])有更多的参与者发生卵巢刺激过度反应(OR=1.978,95%CI 1.138-3.488;p=0.015)。

结论

在 PCOS 组和非 PCOS 组中,促性腺激素的总剂量和获取的卵母细胞数量存在显著差异。与非 PCOS 患者相比,PCOS 且 AMH 水平较高的女性在卵巢刺激后发生过度反应的风险更高。

相似文献

1
IVF outcome with a high level of AMH: a focus on PCOS versus non-PCOS.高 AMH 水平的 IVF 结局:多囊卵巢综合征与非多囊卵巢综合征的重点比较。
BMC Womens Health. 2022 May 14;22(1):172. doi: 10.1186/s12905-022-01756-4.
2
Association of antimüllerian hormone with polycystic ovarian syndrome phenotypes and pregnancy outcomes of in vitro fertilization cycles with fresh embryo transfer.抗缪勒管激素与多囊卵巢综合征表型及新鲜胚胎移植体外受精周期妊娠结局的相关性。
BMC Pregnancy Childbirth. 2022 Mar 2;22(1):171. doi: 10.1186/s12884-022-04518-0.
3
[Value of anti-Müllerian hormone in predicting pregnant outcomes of polycystic ovary syndrome patients undergone assisted reproductive technology].抗苗勒管激素在预测接受辅助生殖技术的多囊卵巢综合征患者妊娠结局中的价值
Zhonghua Fu Chan Ke Za Zhi. 2018 Jan 25;53(1):23-30. doi: 10.3760/cma.j.issn.0529-567X.2018.01.006.
4
Comparing serum basal and follicular fluid levels of anti-Müllerian hormone as a predictor of in vitro fertilization outcomes in patients with and without polycystic ovary syndrome.比较抗苗勒管激素的血清基础水平和卵泡液水平,以此作为多囊卵巢综合征患者与非多囊卵巢综合征患者体外受精结局的预测指标。
Ann Saudi Med. 2010 Nov-Dec;30(6):442-7. doi: 10.4103/0256-4947.71063.
5
Predicting the outcome of different protocols of in vitro fertilization with anti-Muüllerian hormone levels in patients with polycystic ovary syndrome.根据多囊卵巢综合征患者的抗苗勒管激素水平预测不同体外受精方案的结果。
J Int Med Res. 2017 Jun;45(3):1138-1147. doi: 10.1177/0300060517704140. Epub 2017 Apr 28.
6
High serum Antimullerian hormone levels are associated with lower live birth rates in women with polycystic ovarian syndrome undergoing assisted reproductive technology.血清抗苗勒管激素水平高与多囊卵巢综合征患者接受辅助生殖技术后活产率降低相关。
Reprod Biol Endocrinol. 2020 Mar 10;18(1):20. doi: 10.1186/s12958-020-00581-4.
7
[Predictive value of anti-Mullerian hormone levels in serum and follicle fluid for IVF-ET outcomes in patients with polycystic ovarian syndrome].[血清及卵泡液中抗苗勒管激素水平对多囊卵巢综合征患者体外受精-胚胎移植结局的预测价值]
Nan Fang Yi Ke Da Xue Xue Bao. 2013 Apr;33(4):546-9.
8
The role of Letrozole (LE) in controlled ovarian stimulation (COS) in patients at high risk to develop ovarian hyper stimulation syndrome (OHSS). A prospective randomized controlled pilot study.来曲唑(LE)在高风险发生卵巢过度刺激综合征(OHSS)的患者中控制性卵巢刺激(COS)中的作用。一项前瞻性随机对照的初步研究。
J Gynecol Obstet Hum Reprod. 2020 Feb;49(2):101643. doi: 10.1016/j.jogoh.2019.101643. Epub 2019 Sep 26.
9
High Serum Anti-Müllerian Hormone Concentrations Are Associated With Poor Pregnancy Outcome in Fresh IVF/ICSI Cycle but Not Cumulative Live Birth Rate in PCOS Patients.高血清抗苗勒管激素浓度与多囊卵巢综合征患者新鲜体外受精/卵胞浆内单精子注射周期的不良妊娠结局相关,但与累积活产率无关。
Front Endocrinol (Lausanne). 2021 May 26;12:673284. doi: 10.3389/fendo.2021.673284. eCollection 2021.
10
Laparoscopic ovarian drilling before IVF/ICSI in polycystic ovarian syndrome patients with high antimullarian hormone.在高抗苗勒管激素的多囊卵巢综合征患者中,在 IVF/ICSI 之前进行腹腔镜卵巢打孔术。
J Gynecol Obstet Hum Reprod. 2022 Mar;51(3):102324. doi: 10.1016/j.jogoh.2022.102324. Epub 2022 Jan 19.

引用本文的文献

1
The Effect of AMH on Folliculogenesis.抗缪勒管激素对卵泡发生的影响。
Reprod Sci. 2025 May 23. doi: 10.1007/s43032-025-01879-7.
2
Elevated Anti-Müllerian Hormone as a Prognostic Factor for Poor Outcomes of In Vitro Fertilization in Women with Polycystic Ovary Syndrome.抗苗勒管激素升高作为多囊卵巢综合征女性体外受精预后不良的一个预测因素。
Biomedicines. 2023 Nov 27;11(12):3150. doi: 10.3390/biomedicines11123150.
3
Association between serum AMH levels and IVF/ICSI outcomes in patients with polycystic ovary syndrome: a systematic review and meta-analysis.血清 AMH 水平与多囊卵巢综合征患者 IVF/ICSI 结局的关系:系统评价和荟萃分析。
Reprod Biol Endocrinol. 2023 Oct 23;21(1):95. doi: 10.1186/s12958-023-01153-y.
4
The clinical application value of gonadotropin-releasing hormone antagonist combined with low-dose HCG regimen in patients with ovarian hyper-stimulation based on clinical characteristics and laboratory indicators.基于临床特征和实验室指标探讨促性腺激素释放激素拮抗剂联合低剂量人绒毛膜促性腺激素方案在卵巢过度刺激患者中的临床应用价值。
Am J Transl Res. 2023 Aug 15;15(8):5477-5485. eCollection 2023.
5
ApoC3 is expressed in oocytes and increased expression is associated with PCOS progression.载脂蛋白 C3 在卵母细胞中表达,其表达增加与 PCOS 的进展有关。
J Ovarian Res. 2023 Sep 9;16(1):188. doi: 10.1186/s13048-023-01263-6.

本文引用的文献

1
Pregnancy outcomes in women with polycystic ovarian syndrome.多囊卵巢综合征女性的妊娠结局。
Minerva Obstet Gynecol. 2022 Feb;74(1):45-59. doi: 10.23736/S2724-606X.21.04758-4. Epub 2021 Apr 20.
2
High serum Antimullerian hormone levels are associated with lower live birth rates in women with polycystic ovarian syndrome undergoing assisted reproductive technology.血清抗苗勒管激素水平高与多囊卵巢综合征患者接受辅助生殖技术后活产率降低相关。
Reprod Biol Endocrinol. 2020 Mar 10;18(1):20. doi: 10.1186/s12958-020-00581-4.
3
Hormone profiling, including anti-Müllerian hormone (AMH), for the diagnosis of polycystic ovary syndrome (PCOS) and characterization of PCOS phenotypes.激素谱分析,包括抗苗勒管激素(AMH),用于多囊卵巢综合征(PCOS)的诊断和 PCOS 表型的特征描述。
Gynecol Endocrinol. 2019 Jul;35(7):595-600. doi: 10.1080/09513590.2018.1559807. Epub 2019 Jan 22.
4
Are we choosing the correct FSH starting dose during controlled ovarian stimulation for intrauterine insemination cycles? Potential application of a nomogram based on woman's age and markers of ovarian reserve.在进行宫腔内人工授精周期的控制性卵巢刺激时,我们选择的促卵泡生成素(FSH)起始剂量是否正确?基于女性年龄和卵巢储备标志物的列线图的潜在应用。
Arch Gynecol Obstet. 2018 Nov;298(5):1029-1035. doi: 10.1007/s00404-018-4906-2. Epub 2018 Sep 21.
5
Role of AMH as Diagnostic Tool for Polycystic Ovarian Syndrome.抗苗勒管激素作为多囊卵巢综合征诊断工具的作用
J Obstet Gynaecol India. 2018 Apr;68(2):117-122. doi: 10.1007/s13224-017-1066-4. Epub 2017 Nov 15.
6
The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance.多囊卵巢综合征患者排卵障碍性不孕的管理:支持制定全球世卫组织指南的证据分析。
Hum Reprod Update. 2016 Nov;22(6):687-708. doi: 10.1093/humupd/dmw025. Epub 2016 Aug 10.
7
Age-Related Normogram for Ovarian Antral Follicle Count in Women with Polycystic Ovary Syndrome and Comparison with Age Matched Controls Using Magnetic Resonance Imaging.多囊卵巢综合征女性卵巢窦卵泡计数的年龄相关正态分布图以及与年龄匹配对照组的磁共振成像比较
J Clin Diagn Res. 2016 Jan;10(1):TC11-3. doi: 10.7860/JCDR/2016/17334.7136. Epub 2016 Jan 1.
8
Individualized recombinant human follicle-stimulating hormone dosing using the CONSORT calculator in assisted reproductive technology: a large, multicenter, observational study of routine clinical practice.在辅助生殖技术中使用CONSORT计算器进行个体化重组人促卵泡激素给药:一项关于常规临床实践的大型多中心观察性研究。
Drug Healthc Patient Saf. 2015 Apr 15;7:69-76. doi: 10.2147/DHPS.S77320. eCollection 2015.
9
Randomized, controlled, open-label, non-inferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa.用于重组人促卵泡素α个体化给药的CONSORT算法的随机、对照、开放标签、非劣效性研究。
Reprod Biomed Online. 2015 Mar;30(3):248-57. doi: 10.1016/j.rbmo.2014.11.013. Epub 2014 Dec 15.
10
Anti-mullerian hormone as a diagnostic and prognostic tool for PCOS patients.抗苗勒管激素作为多囊卵巢综合征患者的诊断和预后工具。
J Assist Reprod Genet. 2014 Oct;31(10):1311-6. doi: 10.1007/s10815-014-0300-6. Epub 2014 Aug 14.